The TME in NSND patients is more immunoactive than the TME of SD patients, including an increased number of CD8+ TIL cells; increased INF-γactivation; overexpression of immune checkpoint ligands and receptors, such as indoleamine 23-dioxygenase 1 (IDO1) and PD-L1; and higher scores in the pembrolizumab-response signature (96). The gene discussed is IDO1; the disease is Salla disease.